Phase 2 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with multiple myeloma according to Chinese medical guidelines (2022 version).
• People who have already received at least one prior treatment for multiple myeloma that included both lenalidomide and a proteasome inhibitor, and whose disease has either come back or stopped responding to treatment.
• People aged 18 to 75 years (male or female) who are willing and able to use effective birth control throughout the trial period and for 4 weeks after treatment ends, as specified in the trial requirements.
• People whose myeloma can be measured through at least one of the following: a certain level of M protein in the blood, a certain level of M protein in the urine, or an abnormal free light chain level in the blood.
• People whose blood counts meet the trial's minimum requirements for white blood cells, platelets, and haemoglobin — without having needed certain blood-boosting treatments in the 7 days before testing.
• People whose liver and kidney function test results fall within the ranges specified by the trial.
• People who are able to take blood-thinning medications such as low-molecular-weight heparin, warfarin, or aspirin.
• People with a general health performance score of 0–2 on the ECOG scale (a measure of how much a person's illness affects daily activity), and who are expected to live at least 12 weeks.
• People who have voluntarily agreed to participate and have signed a consent form.

Who may not be able to join:

• People who have previously been treated with certain types of cancer drugs, including HDAC inhibitors (other than one specific exception), HSP90 inhibitors, antibody-coupled degradation agents, or valproic acid — or people the treating doctor considers unlikely to tolerate similar drugs, including pomalidomide, thalidomide, or lenalidomide.
• People whose myeloma got worse while being treated with a standard dose of pomalidomide.
• People who have a known allergy to any ingredient in the trial drugs.
• People with a form of myeloma that produces little or no measurable proteins (non-secretory MM), or who have myeloma combined with a related condition called amyloidosis, or a type called plasma cell leukaemia.
• People with a current active blood clot, or who are unable to take blood-thinning medications.
• People who have had another cancer in the past 5 years, with some exceptions such as certain early-stage or fully treated skin cancers or early prostate cancer.
• People who have central nervous system problems that currently require active treatment.
• People with significant nerve damage in their hands or feet rated at grade 3 or higher (confirm with trial site).
• People who require long-term treatment with drugs that suppress the immune system or steroids.
• People with active infections, including active hepatitis B, hepatitis C, HIV, or syphilis, based on specific blood test results.
• People with significant heart problems, including heart failure rated grade 3 or higher, a heart attack within the past 6 months, poorly controlled chest pain within the past 6 months, certain abnormal heart rhythms, abnormal heart electrical readings (QTcF above specific thresholds), or reduced heart pumping function shown on an echocardiogram.
• People who had a serious infection requiring intravenous antibiotics in the 2 weeks before the first dose.
• People who received a donor stem cell transplant within the past 12 months, or who have ongoing graft-versus-host disease or still need immunosuppressive treatment for it.
• People who have taken part in another clinical trial within the past 4 weeks.
• People who have received other cancer treatments (including herbal cancer treatments) within 2 weeks before the first trial dose, with limited exceptions.
• People who still have significant side effects (above grade 1) from previous cancer treatments, with some exceptions such as hair loss.
• People who had major surgery within 4 weeks before the first dose and have not fully recovered.
• People who are pregnant or breastfeeding.
• People who, in the treating doctor's opinion, have other reasons that make participation unsuitable, such as uncontrolled high blood pressure, uncontrolled diabetes, difficulty following medical instructions, or substance misuse.

Important: Always verify eligibility with the trial site directly before applying.